Intellectual Property Rights, Parallel Imports and Strategic Behavior

The existence of parallel imports (PI) raises a number of interesting policy and strategic questions, which are the subject of this survey article. For example, parallel trade is essentially arbitrage within policy-integrated markets of IPR-protected goods, which may have different prices across countries. Thus, we analyze fully two types of price differences that give rise to such arbitrage. First is simple retail-level trade in horizontal markets because consumer prices may differ. Second is the deeper, and more strategic, issue of vertical pricing within the common distribution organization of an original manufacturer selling its goods through wholesale distributors in different markets. This vertical price control problem presents the IPR-holding firm a menu of strategic choices regarding how to compete with PI. Another strategic question is how the existence of PI might affect incentives of IPR holders to invest in research and development (R&D). The global research-based pharmaceutical firms, for example, strongly oppose any relaxation of restrictions against PI of drugs into the United States, arguing that the potential reduction in profits would diminish their ability to innovate. There is a close linkage here with price controls for medicines, which are a key component of national health policies but can give rise to arbitrage through PI. We also discuss the complex economic relationships between PI and other forms of competition policy, or attempts to limit the abuse of market power offered by patents and copyrights. Finally, we review the emerging literature on how policies governing PI may affect international trade agreements.

[1]  Keith E. Maskus,et al.  Reforming U.S. Patent Policy: Getting the Incentives Right , 2006, Innovations: Technology, Governance, Globalization.

[2]  Paul Pecorino Should the U.S. Allow Prescription Drug Reimports from Canada? , 2001, Journal of Health Economics.

[3]  K. Maskus,et al.  Developing and Distributing Essential Medicines to Poor Countries: The DEFEND Proposal , 2001 .

[4]  Richard Schmalensee,et al.  Output and Welfare Implications of Monopolistic Third-Degree Price Discrimination , 1980 .

[5]  C. Mellor,et al.  Intellectual Property Rights and Parallel Imports , 1989 .

[6]  A. Venables,et al.  Completing the internal market in the European Community: Some industry simulations , 1988 .

[7]  Paul Pecorino,et al.  Should the US allow prescription drug reimports from Canada , 2002 .

[8]  Nicolas Schmitt,et al.  Endogenous Vertical Restraints in International Trade , 2000, SSRN Electronic Journal.

[9]  G. Grossman,et al.  Parallel Imports and Price Controls , 2006 .

[10]  Nicolas Schmitt,et al.  Why Parallel Trade May Raise Producers Profits , 2005, SSRN Electronic Journal.

[11]  Frederick M. Abbott First Report (Final) to the Committee on International Trade Law of the International Law Association on the Subject of Parallel Importation , 1998 .

[12]  Aspy P. Palia,et al.  Combating Parallel Importing: Views of US Exporters to the Asia‐Pacific Region , 1991 .

[13]  Yongmin Chen,et al.  Vertical Price Control and Parallel Imports: Theory and Evidence , 1999 .

[14]  David A. Malueg,et al.  Parallel imports, demand dispersion, and international price discrimination* , 1994 .

[15]  T. Valletti,et al.  Differential Pricing, Parallel Trade, and the Incentive to Invest , 2006 .

[16]  L. Telser Why Should Manufacturers Want Fair Trade? , 1960, The Journal of Law and Economics.

[17]  Yongmin Chen,et al.  Vertical Pricing and Parallel Imports , 2005 .

[18]  Stefan Szymanski,et al.  Parallel Trade, International Exhaustion and Intellectual Property Rights: A Welfare Analysis , 2005 .

[19]  Martin Richardson An elementary proposition concerning parallel imports , 2002 .

[20]  H. Varian Price Discrimination and Social Welfare , 1985 .

[21]  Border Ireland,et al.  National Economic Research Associates , 2006 .

[22]  Yongmin Chen,et al.  Parallel Imports in a Model of Vertical Distribution: Theory, Evidence and Policy , 2002 .

[23]  Mattias Ganslandt,et al.  Wholesale Price Discrimination and Parallel Imports , 2007, SSRN Electronic Journal.

[24]  Changying Li,et al.  The impact of parallel imports on investments in cost-reducing research and development , 2006 .

[25]  Mattias Ganslandt,et al.  Parallel imports and the pricing of pharmaceutical products: evidence from the European Union. , 2004, Journal of health economics.

[26]  M. Schwartz Third-Degree Price Discrimination and Output: Generalizing a Welfare Result , 1990 .

[27]  P. Krugman,et al.  Pricing to Market When the Exchange Rate Changes , 1986 .

[28]  Mark A. Groombridge,et al.  The Economic Case for Copyright Owner Control over Parallel Imports , 2005 .

[29]  K. Maskus,et al.  Vertical Distribution, Parallel Trade, and Price Divergence in Integrated Markets , 2005 .

[30]  Changying Li Competition, Parallel Imports and Cost-Reducing Innovation , 2006 .

[31]  Simon P. Anderson,et al.  International Pricing with Costly Consumer Arbitrage , 1999 .

[32]  Joan Robinson,et al.  The Economics of Imperfect Competition. , 1933 .

[33]  T. Valletti,et al.  Parallel Trade, Price Discrimination, Investment and Price Caps , 2005 .

[34]  H. Bale The Conflicts between Parallel Trade and Product Access and Innovation: The Case of Pharmaceuticals , 1998 .

[35]  Ralph A. Winter,et al.  An Economic Theory of Vertical Restraints , 1984 .

[36]  G. Norman,et al.  Optimal Intellectual Property Rights Exhaustion and Humanitarian Assistance during a National Health Emergency , 2003 .

[37]  Joan V. Robinson Economics of imperfect competition , 1969 .